BOSTON SCIENTIFIC CORP reported revenue of $5.44B for the period ended 2026-06-30, +7.5% year on year. Net income was $0.91B, a 16.6% net margin on a 70.7% gross margin. The largest revenue line is Cardiovascular at 67% of the total. Free cash flow for the period was $-0.45B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $5.44B | +7.5% |
| Gross profit | $3.85B | — |
| Operating income | $1.18B | — |
| Net income | $0.91B | +13.8% |
| Gross margin | 70.7% | Net margin 16.6% |
| Revenue Q/Q | +4.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| Cardiovascular | $3.62B | 66.6% |
| Medsurg | $1.82B | 33.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $1.59B | 29.3% |
| SG&A | $1.80B | 33.1% |
| Tax & other | $0.27B | 5.0% |
| Item | Amount |
|---|---|
| Total assets | $45.22B |
| Total liabilities | $20.04B |
| Shareholders' equity | $25.17B |
| Equity / assets | 55.7% |
| Operating cash flow | $1.47B |
| Capital expenditure | $1.93B |
| Free cash flow | $-0.45B |
| Cash conversion (OCF / net income) | 163% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
BMY ・ AVGO ・ BR ・ BRO ・ BF.B ・ BLDR ・ BG ・ BXP ・ CHRW ・ CDNS ・ CPT ・ COF
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies